{"id":10065,"date":"2020-03-23T14:52:19","date_gmt":"2020-03-23T14:52:19","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=10065"},"modified":"2020-12-14T17:58:16","modified_gmt":"2020-12-14T22:58:16","slug":"application-to-fda-for-lonafarnib-approval-is-done","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/ur\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","title":{"rendered":"\u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u0641 \u0688\u06cc \u0627\u06d2 \u06a9\u0648 \u062f\u0631\u062e\u0648\u0627\u0633\u062a \u0645\u06a9\u0645\u0644 \u06c1\u06d2!"},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d3.22\u2033][et_pb_row _builder_version=\u201d3.25\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d][et_pb\u201d=4_column _builder_version=\u201d3.25\u2033 custom_padding=\u201d|||\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text admin_label=\u201dFDA\u201d _builder_version=\u201d4.3.4\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d]<\/p>\n<p style=\"font-weight: 400;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10068  alignleft\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA-300x265.jpg\" alt=\"\" width=\"206\" height=\"182\" \/>\u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u0641 \u0688\u06cc \u0627\u06d2 \u06a9\u0648 \u062f\u0631\u062e\u0648\u0627\u0633\u062a \u0645\u06a9\u0645\u0644 \u06c1\u06d2!\u00a0\u00a0\u00a0<\/strong><\/p>\n<p style=\"font-weight: 400;\">\u06c1\u0645\u0627\u0631\u06cc \u062f\u0646\u06cc\u0627 \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u06a9 \u0627\u0648\u0631 \u0645\u0634\u06a9\u0644 \u0648\u0642\u062a \u06a9\u06d2 \u062f\u0648\u0631\u0627\u0646\u060c \u0645\u062c\u06be\u06d2 \u0627\u06cc\u06a9 \u0631\u0648\u0634\u0646 \u062c\u06af\u06c1 \u0628\u062a\u0627\u062a\u06d2 \u06c1\u0648\u0626\u06d2 \u062e\u0648\u0634\u06cc \u06c1\u0648 \u0631\u06c1\u06cc \u06c1\u06d2: \u0627\u06cc\u06af\u0631 \u0628\u0627\u0626\u06cc\u0648 \u0641\u0627\u0631\u0645\u0627\u0633\u06cc\u0648\u0679\u06cc\u06a9\u0644\u0632 \u0646\u06d2 \u0627\u06cc\u06a9 \u0646\u0626\u06cc \u0688\u0631\u06af \u0627\u06cc\u067e\u0644\u06cc \u06a9\u06cc\u0634\u0646 (NDA) \u062c\u0645\u0639 \u06a9\u0631\u0627\u0626\u06cc \u06c1\u06d2\u060c \u062c\u0633 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 - \u06cc\u0648\u0631\u067e \u0627\u0648\u0631 \u0627\u0645\u0631\u06cc\u06a9\u06c1 \u0645\u06cc\u06ba - \u067e\u06c1\u0644\u06cc \u0628\u0627\u0631 \u062f\u0648\u0627 \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06d2 \u0644\u06cc\u06d2\u06d4 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u0627 \u0639\u0644\u0627\u062c\u06d4<\/p>\n<p style=\"font-weight: 400;\">\u06cc\u06c1 \u06af\u0630\u0627\u0631\u0634 \u0628\u0627\u0631\u06c1 \u0633\u0627\u0644 \u06a9\u06d2 \u062a\u062d\u0642\u06cc\u0642\u06cc \u0627\u0639\u062f\u0627\u062f \u0648 \u0634\u0645\u0627\u0631 \u0627\u0648\u0631 \u0686\u0627\u0631 \u06a9\u0644\u06cc\u0646\u06cc\u06a9\u0644 \u0679\u0631\u0627\u0626\u0644\u0632 \u06a9\u06cc \u0627\u0646\u062a\u06c1\u0627 \u06c1\u06d2\u060c \u06cc\u06c1 \u0633\u0628 PRF \u06a9\u06d2 \u0630\u0631\u06cc\u0639\u06d2 \u0641\u0646\u0688\u0632 \u0641\u0631\u0627\u06c1\u0645 \u06a9\u06cc\u06d2 \u06af\u0626\u06d2 \u06c1\u06cc\u06ba \u0627\u0648\u0631 \u062d\u0648\u0635\u0644\u06c1 \u0645\u0646\u062f \u0628\u0686\u0648\u06ba \u0627\u0648\u0631 \u0627\u0646 \u06a9\u06d2 \u062e\u0627\u0646\u062f\u0627\u0646\u0648\u06ba \u06a9\u06d2 \u0633\u0627\u062a\u06be \u0633\u0627\u062a\u06be PRF \u06a9\u06d2 \u0639\u0637\u06cc\u06c1 \u062f\u06c1\u0646\u062f\u06af\u0627\u0646 \u06a9\u06cc \u0634\u0627\u0646\u062f\u0627\u0631 \u06a9\u0645\u06cc\u0648\u0646\u0679\u06cc \u06a9\u06d2 \u0630\u0631\u06cc\u0639\u06d2 \u0645\u0645\u06a9\u0646 \u06c1\u0648\u0627 \u06c1\u06d2\u06d4<\/p>\n<p style=\"font-weight: 400;\">\u0622\u067e \u0627\u0633 \u062f\u0644\u0686\u0633\u067e \u062e\u0628\u0631 \u06a9\u06d2 \u0628\u0627\u0631\u06d2 \u0645\u06cc\u06ba \u0645\u0632\u06cc\u062f \u067e\u0691\u06be \u0633\u06a9\u062a\u06d2 \u06c1\u06cc\u06ba\u06d4\u00a0<a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf&amp;source=gmail&amp;ust=1585060548571000&amp;usg=AFQjCNE_6Qu8yUr9CDSuYvEVeGJXwXtlYA\">\u06cc\u06c1\u0627\u06ba<\/a>.<\/p>\n<p style=\"font-weight: 400;\">\u06c1\u0645\u0627\u0631\u06cc \u0627\u0645\u06cc\u062f \u06c1\u06d2 \u06a9\u06c1 \u06cc\u06c1 \u062f\u0648\u0627 \u0645\u0646\u0638\u0648\u0631 \u06c1\u0648 \u062c\u0627\u0626\u06d2 \u06af\u06cc\u060c \u062c\u0648 \u0627\u0646 \u0628\u0686\u0648\u06ba \u0627\u0648\u0631 \u0646\u0648\u062c\u0648\u0627\u0646 \u0628\u0627\u0644\u063a\u0648\u06ba \u06a9\u0648 \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u062a\u06a9 \u0631\u0633\u0627\u0626\u06cc \u062d\u0627\u0635\u0644 \u06a9\u0631\u0646\u06d2 \u06a9\u06d2 \u0642\u0627\u0628\u0644 \u0628\u0646\u0627\u0626\u06d2 \u06af\u06cc \u2013 \u062c\u0648 \u0627\u0646\u06c1\u06cc\u06ba \u0645\u0636\u0628\u0648\u0637 \u062f\u0644 \u0627\u0648\u0631 \u0644\u0645\u0628\u06cc \u0632\u0646\u062f\u06af\u06cc \u062f\u06cc\u0646\u06d2 \u06a9\u06d2 \u0644\u06cc\u06d2 \u062f\u06a9\u06be\u0627\u06cc\u0627 \u06af\u06cc\u0627 \u06c1\u06d2 \u2013 \u0637\u0628\u06cc \u0622\u0632\u0645\u0627\u0626\u0634 \u06a9\u06cc \u0628\u062c\u0627\u0626\u06d2 \u0646\u0633\u062e\u06d2 \u06a9\u06d2 \u0630\u0631\u06cc\u0639\u06d2\u06d4<\/p>\n<p style=\"font-weight: 400;\">\u0627\u06af\u0631\u0686\u06c1 2020 \u06a9\u0627 \u0622\u063a\u0627\u0632 \u0628\u06c1\u062a \u0633\u06d2 \u0644\u0648\u06af\u0648\u06ba \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u06a9 \u0645\u0634\u06a9\u0644 \u0633\u0627\u0644 \u06a9\u06d2 \u0637\u0648\u0631 \u067e\u0631 \u06c1\u0648\u0627 \u06c1\u06d2\u060c \u06c1\u0645\u06cc\u06ba \u0622\u067e \u06a9\u06d2 \u0633\u0627\u062a\u06be \u06a9\u0686\u06be \u0627\u0686\u06be\u06cc \u062e\u0628\u0631\u06cc\u06ba \u0628\u062a\u0627\u062a\u06d2 \u06c1\u0648\u0626\u06d2 \u062e\u0648\u0634\u06cc \u06c1\u0648 \u0631\u06c1\u06cc \u06c1\u06d2\u06d4 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646 \u0645\u06cc\u06ba \u06c1\u0645 \u0633\u0628 \u0646\u06d2 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u06d2 \u0633\u0627\u062a\u06be \u0628\u0686\u0648\u06ba \u0627\u0648\u0631 \u0646\u0648\u062c\u0648\u0627\u0646 \u0628\u0627\u0644\u063a\u0648\u06ba \u06a9\u06cc \u0632\u0646\u062f\u06af\u06cc\u0648\u06ba \u067e\u0631 \u0628\u0627\u0645\u0639\u0646\u06cc \u0627\u062b\u0631 \u0688\u0627\u0644\u0646\u06d2 \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u0646\u062a\u06be\u06a9 \u0645\u062d\u0646\u062a \u06a9\u06cc \u06c1\u06d2\u06d4<\/p>\n<p style=\"font-weight: 400;\">\u062a\u062d\u0642\u06cc\u0642 \u06a9\u06cc \u062d\u0645\u0627\u06cc\u062a \u06a9\u0631\u0646\u06d2 \u06a9\u06d2 \u0644\u06cc\u06d2 \u0622\u067e \u0633\u0628 \u06a9\u0627 \u0634\u06a9\u0631\u06cc\u06c1 \u062c\u0633 \u0646\u06d2 \u0646\u06c1 \u0635\u0631\u0641 \u06c1\u0645\u06cc\u06ba \u0627\u0633 \u0627\u06c1\u0645 \u0645\u0642\u0627\u0645 \u067e\u0631 \u067e\u06c1\u0646\u0686\u0627\u06cc\u0627 \u06c1\u06d2 \u0628\u0644\u06a9\u06c1 \u06c1\u0645\u06cc\u06ba \u0646\u0626\u06cc \u062f\u0648\u0627\u0626\u06cc\u06ba \u062f\u0631\u06cc\u0627\u0641\u062a \u06a9\u0631\u0646\u06d2 \u06a9\u06d2 \u0644\u06cc\u06d2 \u06a9\u0627\u0645 \u062c\u0627\u0631\u06cc \u0631\u06a9\u06be\u0646\u06d2 \u06a9\u06cc \u0627\u062c\u0627\u0632\u062a \u0628\u06be\u06cc \u062f\u06cc \u06c1\u06d2 \u062c\u0648 \u0628\u0627\u0644\u0622\u062e\u0631 \u0627\u0646 \u063a\u06cc\u0631 \u0645\u0639\u0645\u0648\u0644\u06cc \u0628\u0686\u0648\u06ba \u06a9\u0648 \u0679\u06be\u06cc\u06a9 \u06a9\u0631 \u062f\u06d2 \u06af\u06cc\u06d4<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>\u06c1\u0645\u0627\u0631\u06cc \u062f\u0646\u06cc\u0627 \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u06a9 \u062f\u0648\u0633\u0631\u06cc \u0635\u0648\u0631\u062a \u0645\u06cc\u06ba \u0645\u0634\u06a9\u0644 \u0648\u0642\u062a \u06a9\u06d2 \u062f\u0648\u0631\u0627\u0646\u060c \u06c1\u0645 \u0627\u06cc\u06a9 \u0631\u0648\u0634\u0646 \u0645\u0642\u0627\u0645 \u06a9\u0627 \u0627\u0634\u062a\u0631\u0627\u06a9 \u06a9\u0631\u062a\u06d2 \u06c1\u0648\u0626\u06d2 \u062e\u0648\u0634 \u06c1\u06cc\u06ba: \u0627\u06cc\u06af\u0631 \u0628\u0627\u0626\u06cc\u0648 \u0641\u0627\u0631\u0645\u0627\u0633\u06cc\u0648\u0679\u06cc\u06a9\u0644\u0632 \u0646\u06d2 \u0627\u06cc\u06a9 \u0646\u0626\u06cc \u0688\u0631\u06af \u0627\u06cc\u067e\u0644\u06cc \u06a9\u06cc\u0634\u0646 (NDA) \u062c\u0645\u0639 \u06a9\u0631\u0627\u0626\u06cc \u06c1\u06d2\u060c \u062c\u0633 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 - \u06cc\u0648\u0631\u067e \u0627\u0648\u0631 \u0627\u0645\u0631\u06cc\u06a9\u06c1 \u0645\u06cc\u06ba - \u067e\u06c1\u0644\u06cc \u0628\u0627\u0631 \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u062f\u0648\u0627 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u0627 \u0639\u0644\u0627\u062c\u06d4<\/p>","protected":false},"author":2,"featured_media":10068,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-10065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/ur\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/ur\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-23T14:52:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-14T22:58:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"529\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u0645\u0646\u0679\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"Application to FDA for lonafarnib approval is COMPLETE!\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"ur\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\",\"name\":\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"description\":\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb\"},\"inLanguage\":\"ur\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ur\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\",\"width\":600,\"height\":529},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application to FDA for lonafarnib approval is COMPLETE!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ur\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ur\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ur\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/ur\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u0641 \u0688\u06cc \u0627\u06d2 \u06a9\u0648 \u062f\u0631\u062e\u0648\u0627\u0633\u062a \u0645\u06a9\u0645\u0644 \u06c1\u06d2! - \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646","description":"\u06c1\u0645\u0627\u0631\u06cc \u062f\u0646\u06cc\u0627 \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u06a9 \u062f\u0648\u0633\u0631\u06cc \u0635\u0648\u0631\u062a \u0645\u06cc\u06ba \u0645\u0634\u06a9\u0644 \u0648\u0642\u062a \u06a9\u06d2 \u062f\u0648\u0631\u0627\u0646\u060c \u06c1\u0645 \u0627\u06cc\u06a9 \u0631\u0648\u0634\u0646 \u0645\u0642\u0627\u0645 \u06a9\u0627 \u0627\u0634\u062a\u0631\u0627\u06a9 \u06a9\u0631\u062a\u06d2 \u06c1\u0648\u0626\u06d2 \u062e\u0648\u0634 \u06c1\u06cc\u06ba: Eiger BioFarmaceuticals \u0646\u06d2 \u0627\u06cc\u06a9 \u0646\u0626\u06cc \u0688\u0631\u06af \u0627\u06cc\u067e\u0644\u06cc \u06a9\u06cc\u0634\u0646 (NDA) \u062c\u0645\u0639 \u06a9\u0631\u0627\u0626\u06cc \u06c1\u06d2\u060c \u062c\u0633 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 - \u06cc\u0648\u0631\u067e \u0627\u0648\u0631 \u0627\u0645\u0631\u06cc\u06a9\u06c1 \u0645\u06cc\u06ba - \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u06d2 \u0644\u06cc\u06d2 \u067e\u06c1\u0644\u06cc \u0628\u0627\u0631 \u0639\u0644\u0627\u062c \u06a9\u06d2 \u0637\u0648\u0631 \u067e\u0631 \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u062f\u0648\u0627 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u062d\u0627\u0635\u0644 \u06a9\u06cc \u06af\u0626\u06cc \u06c1\u06d2\u06d4","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/ur\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_locale":"en_US","og_type":"article","og_title":"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation","og_description":"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/ur\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2020-03-23T14:52:19+00:00","article_modified_time":"2020-12-14T22:58:16+00:00","og_image":[{"width":600,"height":529,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 \u0645\u0646\u0679"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"Application to FDA for lonafarnib approval is COMPLETE!","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"wordCount":294,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","articleSection":["News"],"inLanguage":"ur"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","url":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","name":"\u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u0641 \u0688\u06cc \u0627\u06d2 \u06a9\u0648 \u062f\u0631\u062e\u0648\u0627\u0633\u062a \u0645\u06a9\u0645\u0644 \u06c1\u06d2! - \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","description":"\u06c1\u0645\u0627\u0631\u06cc \u062f\u0646\u06cc\u0627 \u06a9\u06d2 \u0644\u06cc\u06d2 \u0627\u06cc\u06a9 \u062f\u0648\u0633\u0631\u06cc \u0635\u0648\u0631\u062a \u0645\u06cc\u06ba \u0645\u0634\u06a9\u0644 \u0648\u0642\u062a \u06a9\u06d2 \u062f\u0648\u0631\u0627\u0646\u060c \u06c1\u0645 \u0627\u06cc\u06a9 \u0631\u0648\u0634\u0646 \u0645\u0642\u0627\u0645 \u06a9\u0627 \u0627\u0634\u062a\u0631\u0627\u06a9 \u06a9\u0631\u062a\u06d2 \u06c1\u0648\u0626\u06d2 \u062e\u0648\u0634 \u06c1\u06cc\u06ba: Eiger BioFarmaceuticals \u0646\u06d2 \u0627\u06cc\u06a9 \u0646\u0626\u06cc \u0688\u0631\u06af \u0627\u06cc\u067e\u0644\u06cc \u06a9\u06cc\u0634\u0646 (NDA) \u062c\u0645\u0639 \u06a9\u0631\u0627\u0626\u06cc \u06c1\u06d2\u060c \u062c\u0633 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u0644\u06cc\u06d2 - \u06cc\u0648\u0631\u067e \u0627\u0648\u0631 \u0627\u0645\u0631\u06cc\u06a9\u06c1 \u0645\u06cc\u06ba - \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u06d2 \u0644\u06cc\u06d2 \u067e\u06c1\u0644\u06cc \u0628\u0627\u0631 \u0639\u0644\u0627\u062c \u06a9\u06d2 \u0637\u0648\u0631 \u067e\u0631 \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u062f\u0648\u0627 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u062d\u0627\u0635\u0644 \u06a9\u06cc \u06af\u0626\u06cc \u06c1\u06d2\u06d4","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb"},"inLanguage":"ur","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"]}]},{"@type":"ImageObject","inLanguage":"ur","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","width":600,"height":529},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Application to FDA for lonafarnib approval is COMPLETE!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646","description":"\u0628\u0686\u0648\u06ba \u06a9\u06d2 \u0644\u06cc\u06d2 \u2665 \u0639\u0644\u0627\u062c \u06a9\u06d2 \u0644\u06cc\u06d2","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ur"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ur","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\u06a9\u06cc\u0631\u0646 \u0628\u06cc\u0679\u0648\u0631\u0646\u06d2","image":{"@type":"ImageObject","inLanguage":"ur","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/ur\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/posts\/10065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/comments?post=10065"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/posts\/10065\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/media\/10068"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/media?parent=10065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/categories?post=10065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/tags?post=10065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}